Case Report

Ustekinumab and Vedolizumab Dual Biologic Therapy in the Treatment of Crohn’s Disease

Eddie Y. Liu and Dustin E. Loomes

1University of Saskatchewan, Saskatoon, SK, Canada
2University of British Columbia, Vancouver, BC, Canada

Correspondence should be addressed to Eddie Y. Liu; eliu329@gmail.com

Received 10 July 2017; Accepted 15 October 2017; Published 8 November 2017

1.Introduction
Crohn’s disease is an inflammatory condition of the gastrointestinal tract that is associated with significant morbidity [1]. Medical therapies that are commonly used include oral 5-aminosalicylates, antibiotics, conventional glucocorticoids, nonsystemic glucocorticoids, immunomodulators, and biologic therapies. In patients who do not respond to medical therapy, surgical resection can lead to clinical remission. However, surgical resection is not curative and most patients eventually relapse [2].

2. Case Presentation
We present a case of refractory ileocolonic Crohn’s disease in a 27-year-old female treated with dual ustekinumab and vedolizumab biologic therapy. She had mucosal healing for the first time in 13 years after a 10-month treatment of ustekinumab overlapped with 6 months of vedolizumab. No side effects were observed during the 6 months of dual biologic therapy. Short-term dual biologic therapy may be considered as a treatment option for induction of remission in refractory cases of Crohn’s disease.

infliximab with the addition of methotrexate combination therapy. Colonoscopy showed ongoing deep serpiginous ileal ulcers, colonic aphthous ulceration, and worsening deep rectal ulceration (Figure 1). As her previous ustekinumab therapy had not included intravenous loading, infliximab combo therapy was stopped and she was restarted on ustekinumab with induction dosing and then 90 mg subcutaneously every 4 weeks, in combination with azathioprine. Azathioprine metabolites showed significant shunting with a low 6-thioguanine and an elevated 6-methyl mercaptopurine, prompting a dose reduction to 25 mg daily and addition of allopurinol 50 mg daily. Mezavant 4 g daily, salofalk 1 g suppositories, and Entocort 9 mg daily were also started. Despite this, symptoms continued, with magnetic resonance enterography and fecal calprotectin (FCP) both showing ongoing evidence of inflammation five months post initiation of ustekinumab. After careful consideration and discussion of known and unknown risks of dual biologic therapy, vedolizumab was added, and ustekinumab was decreased to every 8 weeks. Five months after adding vedolizumab to ustekinumab, FCP decreased to 93 mcg per gram, and abdominal pain and nausea began to improve. Colonoscopy 6 months after dual biologic therapy showed mucosal healing of the ileum and colon (Figure 2), which is the first time the patient has had mucosal healing since
diagnosis. No side effects from her medical therapy have arisen thus far. Repeat azathioprine metabolites targeting a 6-thioguanine of 125 pmol/8 × 10⁸ RBC are pending, and we plan to obtain an ustekinumab level and stop dual biologic therapy, continuing with vedolizumab and azathioprine combination therapy.

3. Discussion

This case demonstrates the benefit of using dual biologic therapy with ustekinumab and vedolizumab in treating severe ileocolonic Crohn’s disease. Brief addition of vedolizumab during infliximab maintenance therapy has been described in treating ileocolonic Crohn’s disease [3]. There is a paucity of data on the safety of dual biologics. In a small case series of 3 patients given 2-3 doses of ustekinumab during anti-TNF therapy, no adverse effects in a median follow-up of 21 months emerged [4]. Additionally, no adverse effects arose after 10 months of vedolizumab and etanercept dual therapy in treating chronic pouchitis and spondyloarthritis [5]. Although short-term dual biologic therapy may be considered as a treatment option for induction of remission in refractory cases of Crohn’s disease, larger studies are needed to assess the efficacy and safety of this approach.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

References

[1] F. L. Wolters, M. G. Russel, and R. W. Stockbrügger, “Systematic review: has disease outcome in Crohn’s disease changed during the last four decades?,” *Alimentary Pharmacology and Therapeutics*, vol. 20, no. 5, pp. 483–496, 2004.
[2] A. N. Ananthakrishnan, “Surgery for Crohn’s disease: look harder, act faster,” *Lancet*, vol. 385, no. 9976, pp. 1370–1371, 2015.
[3] R. Hirten, R. S. Longman, B. P. Bosworth, A. Steinlauf, and E. Scherl, “Vedolizumab and infliximab combination therapy in the treatment of Crohn’s disease,” *American Journal of Gastroenterology*, vol. 110, no. 12, pp. 1737–1738, 2015.
[4] C. Yzet, J. L. Dupas, and M. Fumery, “Ustekinumab and anti-TNF combination therapy in patients with inflammatory bowel disease,” *The American Journal of Gastroenterology*, vol. 111, no. 5, pp. 748–749, 2016.
[5] J. Bethge, S. Meffert, M. Ellrichmann, C. Conrad, S. Nikolaus, and S. Schreiber, “Combination therapy with vedolizumab and etanercept in a patient with pouchitis and spondylarthritis,” *BMJ Open Gastroenterology*, vol. 4, no. 1, p. e000127, 2017.